Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma

NCT01055522 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT01055522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01055522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Definition and Activity Evaluation Study of the Tumor-Targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Combination With Dacarbazine in Patients With Metastatic Melanoma
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2008
Completion date
February 28, 2014
Enrollment
102 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma